A Quantitative Assessment of Epidemiological Parameters Required to Investigate COVID-19 Burden
Overview
Public Health
Authors
Affiliations
Solid estimates describing the clinical course of SARS-CoV-2 infections are still lacking due to under-ascertainment of asymptomatic and mild-disease cases. In this work, we quantify age-specific probabilities of transitions between stages defining the natural history of SARS-CoV-2 infection from 1965 SARS-CoV-2 positive individuals identified in Italy between March and April 2020 among contacts of confirmed cases. Infected contacts of cases were confirmed via RT-PCR tests as part of contact tracing activities or retrospectively via IgG serological tests and followed-up for symptoms and clinical outcomes. In addition, we provide estimates of time intervals between key events defining the clinical progression of cases as obtained from a larger sample, consisting of 95,371 infections ascertained between February and July 2020. We found that being older than 60 years of age was associated with a 39.9% (95%CI: 36.2-43.6%) likelihood of developing respiratory symptoms or fever ≥ 37.5 °C after SARS-CoV-2 infection; the 22.3% (95%CI: 19.3-25.6%) of the infections in this age group required hospital care and the 1% (95%CI: 0.4-2.1%) were admitted to an intensive care unit (ICU). The corresponding proportions in individuals younger than 60 years were estimated at 27.9% (95%CI: 25.4-30.4%), 8.8% (95%CI: 7.3-10.5%) and 0.4% (95%CI: 0.1-0.9%), respectively. The infection fatality ratio (IFR) ranged from 0.2% (95%CI: 0.0-0.6%) in individuals younger than 60 years to 12.3% (95%CI: 6.9-19.7%) for those aged 80 years or more; the case fatality ratio (CFR) in these two age classes was 0.6% (95%CI: 0.1-2%) and 19.2% (95%CI: 10.9-30.1%), respectively. The median length of stay in hospital was 10 (IQR: 3-21) days; the length of stay in ICU was 11 (IQR: 6-19) days. The obtained estimates provide insights into the epidemiology of COVID-19 and could be instrumental to refine mathematical modeling work supporting public health decisions.
Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality.
Marziano V, Guzzetta G, Menegale F, Sacco C, Petrone D, Urdiales A Influenza Other Respir Viruses. 2023; 17(8):e13181.
PMID: 37599801 PMC: 10432583. DOI: 10.1111/irv.13181.
Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply.
Galli M, Zardini A, Gamshie W, Santini S, Tsegaye A, Trentini F Sci Rep. 2023; 13(1):5586.
PMID: 37019980 PMC: 10075159. DOI: 10.1038/s41598-023-32501-y.
Kun A, Hubai A, Kral A, Mokos J, Mikulecz B, Radvanyi A Biol Futur. 2023; 74(1-2):69-80.
PMID: 37002448 PMC: 10066022. DOI: 10.1007/s42977-023-00159-2.
A Markovian model for the spread of the SARS-CoV-2 virus.
Palopoli L, Fontanelli D, Frego M, Roveri M Automatica (Oxf). 2023; 151:110921.
PMID: 36817632 PMC: 9928740. DOI: 10.1016/j.automatica.2023.110921.
Model-based evaluation of alternative reactive class closure strategies against COVID-19.
Liu Q, Zhang J, Peng C, Litvinova M, Huang S, Poletti P Nat Commun. 2022; 13(1):322.
PMID: 35031600 PMC: 8760266. DOI: 10.1038/s41467-021-27939-5.